This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

A Beaten-Down Biotech Stock Poised for an Epic Short Squeeze

Wall Street likely overreacted to the poor vintafolide results for ovarian cancer, since the stock has collapsed from over $17.50 to its recent 52-week low of $6.01 a share. That collapse pushed shares of ECYT into extremely oversold territory, since the stock traded at a relative strength index reading of well below 30 for over a month. That overreaction was a major win for the short-sellers, but those shorts might want to think about locking in profits and getting long this stock now, since it's technically changing its tone from bearish to bullish rapidly.

If you take a look at the chart for ECYT, you'll notice that this stock recently formed a double bottom chart pattern at $6.01 to $6.05 a share. Following that bottom, shares of ECYT have started to uptrend and break out above some near-term overhead resistance levels at $6.62 to $6.82 a share. That breakout is now setting up shares of ECYT to trigger a much bigger breakout that could give this stock a chance to make an explosive move back into its previous gap-down-day zone from early May that started above $17.50 a share.

Traders should now look for a long-biased trades in ECYT as long as it's trending above those double-bottom support levels at $6.01 to $6.05 a share and then once it breaks out above some key near-term overhead resistance at $7.34 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.93 million shares. If that breakout materializes soon, then ECYT will set up to re-fill some of its previous gap-down-day zone from May that started just above $17.50 a share. Some possible upside targets if ECYT gets into that gap with strong upside volume flows are $10 to $12 a share.

If ECYT breaks out into that gap with volume, then this stock could see an epic short-squeeze that sends shares screaming sharply higher. The current short interest as a percentage of the float for ECYT is extremely high at 16.8%. That means that out of the 36.96 million shares in the tradable float, 6.24 million shares are sold short by the bears. This is a large short interest on a stock with a relatively low tradable float. It won't take much to send this stock ripping higher, so watch for that breakout with volume to potential ignite the next big biotech short-squeeze.

-- Written by Roberto Pedone in Delafield, Wis.


Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned. Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including and You can follow Pedone on Twitter at or @zerosum24.
2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs